Provided by Tiger Fintech (Singapore) Pte. Ltd.

AKESO

82.250
+0.3000.37%
Volume:8.22M
Turnover:666.94M
Market Cap:73.86B
PE:-124.61
High:83.200
Open:81.950
Low:79.300
Close:81.950
Loading ...

Akeso's Pd-1/Ctla-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations--Third Approved Indication for Cadonilimab

THOMSON REUTERS
·
05 Jun

Akeso Inc. Receives NMPA Approval for Cadonilimab as First-Line Treatment for Cervical Cancer

Reuters
·
05 Jun

Akeso - Nmpa Approved Snda for Cadonilimab as First-Line Treatment for Cervical Cancer

THOMSON REUTERS
·
05 Jun

Akeso Hits Snag with Less Favorable Clinical Trial Data for Lung Cancer Treatment; Shares Rise 7%

MT Newswires Live
·
03 Jun

Akeso Grants Share Options, Restricted Share Units

MT Newswires Live
·
26 May

Akeso Inc. Announces New Grant of Share Options and Restricted Share Units for Directors and Employees

Reuters
·
26 May

Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid. -- Barrons.com

Dow Jones
·
20 May

Nomura Downgrades Akeso to Neutral From Buy, Adjusts Price Target to HK$99.66 From HK$75.14

MT Newswires Live
·
28 Apr

Akeso Gets China Nod for Lung Cancer Drug Indication

MT Newswires Live
·
28 Apr

Ivonescimab Receives Nmpa Approval for First-Line Treatment of Pd-L1-Positive Nsclc, Based on Breakthrough Head to Head Phase Iii Trial Demonstrating Superior Efficacy Over Pembrolizumab

THOMSON REUTERS
·
26 Apr

US FDA Approves Nasopharyngeal Carcinoma Drug

MT Newswires Live
·
25 Apr

BRIEF-Akeso Says FDA Approved Anniko (Penpulimab-Kcqx, Pd-1) In Two Indications

Reuters
·
25 Apr

Akeso Announces FDA Approval for Penpulimab-Kcqx in Two Bla Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma

THOMSON REUTERS
·
25 Apr

Akeso - FDA Approved Anniko (Penpulimab-Kcqx, Pd-1) in Two Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma

THOMSON REUTERS
·
25 Apr

FDA: on April 23, Approves Penpulimab-Kcqx for Non-Keratinizing Nasopharyngeal Carcinoma

THOMSON REUTERS
·
25 Apr

HK Movers | Biotech Stocks Jump With ImmuneOnco up 10%

Tiger Newspress
·
24 Apr

Akeso's Lung Cancer Drug Meets Primary Endpoints in China Phase 3 Trial; Shares Rise 5%

MT Newswires Live
·
23 Apr

HK Movers | Biotech Stocks Rally With Zai Lab up 8%

Tiger Newspress
·
23 Apr

Ivonescimab in Combination With Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (Sq-Nsclc) VS. Tislelizumab in Combination With Chemotherapy

THOMSON REUTERS
·
23 Apr

Akeso's NDA for Plaque Psoriasis Drug Gets China Nod

MT Newswires Live
·
22 Apr